EMEA-002687-PIP01-19 - paediatric investigation plan

levodopa

carbidopa

Key facts

• Active substance:
  • levodopa
  • carbidopa
• Therapeutic area:
  Neurology
• Decision number:
  P/0068/2020
• PIP number:
  EMEA-002687-PIP01-19
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of Parkinson's disease
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  18/03/2020
• Compliance check done:
  No

Decision

P/0068/2020: EMA decision of 18 March 2020 on the granting of a product specific waiver for Levodopa / Carbidopa (EMEA-002687-PIP01-19)

Adopted Reference Number: EMA/83476/2020